Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

Abstract Background To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological a...

Full description

Bibliographic Details
Main Authors: Virginia Pérez-Grijalba, Javier Arbizu, Judith Romero, Elena Prieto, Pedro Pesini, Leticia Sarasa, Fernando Guillen, Inmaculada Monleón, Itziar San-José, Pablo Martínez-Lage, Josep Munuera, Isabel Hernández, Mar Buendía, Oscar Sotolongo-Grau, Montserrat Alegret, Agustín Ruiz, Lluis Tárraga, Mercè Boada, Manuel Sarasa, The AB255 Study Group
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
Plasma
Amyloid-beta
FDG-PET
Biomarker
Preclinical Alzheimer’s disease
Amyloid-PET
Online Access:https://doi.org/10.1186/s13195-019-0549-1

Internet

https://doi.org/10.1186/s13195-019-0549-1

Similar Items